Susquehanna International Group
ELTX icon

Susquehanna International Group’s Elicio Therapeutics ELTX Stock Holding History

Susquehanna International Group’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482K Buy
+45,100
New +$435K ﹤0.01% 9772

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ELTX Position: Q1 2026 in Review

Susquehanna International Group increased its Elicio Therapeutics (ELTX) stake by 11% in Q1 2026, buying an estimated $65.2K and bringing the position to 70,804 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #8615.

Susquehanna International Group first reported a position in ELTX in Q2 2022 and has held it in 7 quarters since. The position peaked at $1.32M in Q3 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Susquehanna International Group held 70,804 shares of Elicio Therapeutics worth $757K as of Q1 2026.
  • Susquehanna International Group bought 6,752 Elicio Therapeutics shares in Q1 2026, an estimated $65.2K.
  • Elicio Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8615 holding.
  • Susquehanna International Group first reported a position in Elicio Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • Susquehanna International Group's Elicio Therapeutics position peaked at $1.32M in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.